The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

and chronic obstructive pulmonary disease (COPD). These conditions can compromise the immune system, making it harder to ...

Arexvy shows 62.9% efficacy against RSV-LRTD over three seasons in adults aged 60 and older. The vaccine demonstrates 67.4% efficacy against severe RSV-LRTD, with consistent safety data.

Additional data from the phase 3 trial showed the vaccine came with a 94.1% effectiveness in preventing severe RSV when people got it during the first season and 64.2% a year later, the company ...

PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine ... as chronic obstructive pulmonary disease (COPD ...

GSK RSV Shot 43% Effective Against Severe Disease in Third Year GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was ... to Worse Outcomes in Pulmonary Embolism Location ...

An all-encompassing guide to understanding vaccines. CDC Recommends People Ages 50 to 64 Get Pneumococcal VaccinesThe CDC now says everyone 50 to 64 years old should get a pneumococcal vaccine to ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...